LANREOTIDE

The PBAC recommended lanreotide LACREO 60 mg/0.2 mL injection 0.2 mL syringe, LACREO 90 mg/0.3 mL injection 0.3 mL syringe and LACREO 120 mg/0.5 mL injection 0.5 mL syringe for the treatment of acromegaly, functional carcinoid tumour and non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET). The PBAC advised the equi-effective doses to be 1 mg LACREO equals 1 mg Somatuline Autogel. The PBAC noted and welcomed input from an organisation that outlined the physical, psychological and daily burden for patients living with acromegaly, functional carcinoid tumour and GEP-NET. Input from this organisation noted the benefits of lanreotide (LACREO) included reduced treatment and financial burden and improvement in overall quality of life. The PBAC advised that lanreotide LACREO, Mytolac and Somatuline Autogel will be considered equivalent for the purposes of substitution, and flow on changes to other brands will be noted.